Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma-Reference-Cited by-同舟云学术

Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma

Published:2022-08 Issue: Volume:533 Page:71-78
ISSN:0009-8981
Container-title:Clinica Chimica Acta
language:en
Short-container-title:Clinica Chimica Acta

Author:

Rozeman Elisa A.,Versluis Judith M.,Moritz Ruben,Wilgenhof Sofie,van Thienen Johannes V.,Haanen John B.A.G.,van de Heuvel Michel M.,Blank Christian U.,van Rossum Huub H.

Publisher

Elsevier BV

Subject

Biochemistry (medical),Clinical Biochemistry,Biochemistry,General Medicine

Reference32 articles.

1. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Luke;Nat. Rev. Clin. Oncol.,2017

2. Luke JJ. Comprehensive clinical trial data summation for BRAF-MEK inhibition and checkpoint immunotherapy in metastatic melanoma. Oncologist. 2019.

3. Immunological effects of BRAF+MEK inhibition;Ascierto;OncoImmunology.,2018

4. Advanced melanoma: current treatment options, biomarkers, and future perspectives;Rozeman;Am. J. Clin. Dermatol.,2018

5. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma;Ribas;JAMA,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alarmins in cutaneous malignant melanoma: An updated overview of emerging evidence on their pathogenetic, diagnostic, prognostic, and therapeutic role;The Journal of Dermatology;2024-05-22

2. Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update;Expert Review of Molecular Diagnostics;2024-02

3. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1;Frontiers in Oncology;2023-08-17

4. Microneedles-mediated drug delivery system for the diagnosis and treatment of melanoma;Colloids and Surfaces B: Biointerfaces;2022-11

5. Circulating biomarkers of response to immunotherapy and immune-related adverse events;Expert Review of Molecular Diagnostics;2022-09-02